Join Nuventra on April 29 for an AAPS eChalk Talk discussing strategies to keep your program moving forward.
During these unprecedented times, it’s important to keep your drug development program moving toward approval. This session will highlight strategic actions to take right now to ensure that you minimize delays including:
- What to do in the interim if your study is on pause
- Considerations for planning and start-up of new studies
- What can you be doing now to minimize delays as backlogged studies initiate
Registration is free for AAPS members
Meet the Presenters
Mark A. Bush, Ph.D.
Dr. Bush has over 20 years of experience in clinical pharmacology and pharmacokinetics with a particular focus in clinical pharmacology study design and interpretation. His therapeutic concentrations include endocrinology and metabolism in early phases of development. Dr. Bush has worked on over 100 PK and population PK analyses.
Betty Hussey, Pharm.D.
Vice President, Clinical Pharmacology & Pharmacokinetics
Dr. Hussey has over 30 years of extensive leadership and experience in drug development, clinical development, clinical pharmacology, and pharmacokinetics across multiple therapeutic areas and all phases of development. Dr. Hussey’s primary therapeutic area experience includes dermatology, metabolic diseases, CNS, antivirals, anti-infectives with focus on early proof-of-concept.